L-745870

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H19ClN4
Molecular Weight	326.823
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C(C=C1)N2CCN(CC3=CNC4=C3C=CC=N4)CC2

InChI

InChIKey=OGJGQVFWEPNYSB-UHFFFAOYSA-N

InChI=1S/C18H19ClN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)

HIDE SMILES / InChI

Molecular Formula	C18H19ClN4
Molecular Weight	326.823
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9353380\|https://www.ncbi.nlm.nih.gov/pubmed/9400001	Antagonist 2778		1.0 nM [IC50]

PubMed

Title	Date	PubMed
3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor.	1996 May 10	8642550
Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine.	2001 Apr 12	11312915
Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.	2001 Jun 4	11378358
Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex.	2002 Nov 1	12417643
L-745,870 suppresses the nighttime serotonin N-acetyltransferase activity in chick retina: in vivo evidence for agonist activity at D4-dopamine receptors.	2003 Mar	12658371
Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus.	2004 Sep 13	15363981
Tonic modulation of inhibition by dopamine D4 receptors in the rat hippocampus.	2005	15476261
2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.	2005 Jul	15992586
Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: Involvement of central oxytocin.	2007 Mar	17164075
Dopamine D(4) receptor activation decreases the expression of mu-opioid receptors in the rat striatum.	2007 May 20	17366605
A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice.	2008 Jun	18423451
Dopamine D4 receptor antagonist L745,870 abolishes cognitive effects of intracerebroventricular angiotensin IV and des-Phe(6)-Ang IV in rats.	2009 Feb	18835699
Dopaminergic modulation of risk-based decision making.	2009 Feb	18668030
p-Hydroxyamphetamine causes prepulse inhibition disruptions in mice: contribution of dopamine neurotransmission.	2010 Dec 25	20540968
D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD.	2010 Jan	19840852
Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis.	2011 Nov	21867702

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 15:11:21 GMT 2023` Edited by `admin` on `Sat Dec 16 15:11:21 GMT 2023`
Record UNII	J3OLN3XSX7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

L-745870

Code

English

1H-PYRROLO(2,3-B)PYRIDINE, 3-((4-(4-CHLOROPHENYL)-1-PIPERAZINYL)METHYL)-

Systematic Name

English

3-((4-(4-CHLOROPHENYL)-1-PIPERAZINYL)METHYL)-1H-PYRROLO(2,3-B)PYRIDINE

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID40415513